

REMARKS

This supplemental response is being filed in order to correct an inadvertent typographical error contained in the previous response, in which single brackets, as opposed to double brackets, were used to indicate deletion of certain limitations from pending Claims 23 and 33. This error was brought to Applicant's attention by Examiner Sarvamangala Devi in the USPTO Communication dated December 29, 2010. The inadvertent typographical error has been corrected in pending Claims 23 and 33 in this supplemental response. The claims of this supplemental response are identical to those of the previous response in all other respects.

Applicant respectfully requests that the Commissioner replace the claims from the previous response with the claims from this supplemental response.

No additional fees associated with this submission, or otherwise associated the instant case, are believed due. However, if such a fee is due, the Commissioner is hereby authorized to charge payment of any such fees to Applicant's Deposit Account No. 010535 referencing Docket No. 235/013US. Additionally, the Commissioner is hereby authorized to charge payment or credit overpayment of any fees during the pendency of this application to Applicant's Deposit Account No. 010535.

Respectfully submitted,
AMYLIN PHARMACEUTICALS, INC.

Dated: January 4, 2011

/Timothy E. Torchia/
Timothy E. Torchia
Registration No. 36,700

AMYLIN PHARMACEUTICALS, INC.
9360 Towne Centre Drive
San Diego, CA 92121
Telephone: (858) 552-2200
Fax: (858) 552-1936